Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
US Army
Chubb
Federal Trade Commission
Covington
Cipla
Medtronic
Dow
Daiichi Sankyo
Fuji

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,741,926

« Back to Dashboard

Which drugs does patent 8,741,926 protect, and when does it expire?

Patent 8,741,926 protects OLYSIO and is included in one NDA.

This patent has fifty-one patent family members in thirty-eight countries.
Summary for Patent: 8,741,926
Title:Macrocyclic inhibitors of hepatitis C virus
Abstract: Inhibitors of HCV replication of formula (I) ##STR00001## and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 is halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, phenyl, or Het; R.sup.6 is C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
Inventor(s): Simmen; Kenneth Alan (Tervuren, BE), De Kock; Herman Augustinus (Arendonk, BE), Raboisson; Pierre Jean-Marie Bernard (Sterrebeek, BE), Hu; Lili (Mechelen, BE), Tahri; Abdellah (Anderlecht, BE), Surleraux; Dominique Louis Nestor Ghislain (Braine-le-chateau, BE), Nilsson; Karl Magnus (Goteborg, SE), Samuelsson; Bengt Bertil (Skarholmen, SE), Rosenquist; .ANG.sa Annica Kristina (Huddinge, SE), Ivanov; Vladimir (Moscow, RU), Pelcman; Mikael (Alvsjo, SE), Belfrage; Anna Karin Gertrud Linnea (Uppsala, SE), Johansson; Per-Ola Mikael (Huddinge, SE), Vendeville; Sandrine Marie Helene (Etterbeek, BE)
Assignee: Janssen R&D Ireland (Little Island, County Cork, IE) Medivir AB (Huddinge, SE)
Application Number:13/687,037
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 8,741,926

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Prods OLYSIO simeprevir sodium CAPSULE;ORAL 205123-001 Nov 22, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING HEPATITIS C ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,741,926

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05107074Jul 29, 2005
05107417Aug 11, 2005
06101280Feb 3, 2006

Non-Orange Book US Patents Family Members for Patent 8,741,926

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,148,399 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
8,754,106 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
9,040,562 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
9,623,022 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
9,856,265 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
9,353,103 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
8,153,800 Macrocyclic inhibitors of hepatitis C virus ➤ Sign Up
8,349,869 Macrocylic inhibitors of hepatitis C virus ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,741,926

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 95245 ➤ Sign Up
Taiwan I358411 ➤ Sign Up
Taiwan 200745117 ➤ Sign Up
El Salvador 2008002642 ➤ Sign Up
Slovenia 2322516 ➤ Sign Up
Slovenia 1912999 ➤ Sign Up
Singapore 163617 ➤ Sign Up
Serbia 54473 ➤ Sign Up
Serbia 51743 ➤ Sign Up
Portugal 2322516 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
US Department of Justice
Covington
Federal Trade Commission
Harvard Business School
Medtronic
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot